Assertio, a specialty pharmaceutical company, completed the acquisition of Spectrum Pharmaceuticals, a commercial stage biopharmaceutical company, for $291m. “We are excited to combine with Assertio in a transaction that will deliver significant value to our stockholders and the opportunity to share in the future upside of ROLVEDON. Our mission at Spectrum has always been to make a difference in the lives of patients and with Assertio, we have a partner that will enable us to deliver on this promise. Our combined assets and commercial infrastructure will position us to accelerate ROLVEDON’s launch for the benefit of patients, maximize its potential and drive further growth. We are proud of the launch trajectory our team has achieved with ROLVEDON and look forward to an exciting new chapter,” Tom Riga, Spectrum Pharmaceuticals President and CEO. On July 27, 2023, Assertio announces favorable vote on proposed acquisition of Spectrum Pharmaceuticals.